Ponce RA - Search Results

1

Immunomodulation and lymphoma in humans.

Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M. Ponce RA, et al. J Immunotoxicol. 2014 Jan-Mar;11(1):1-12. doi: 10.3109/1547691X.2013.798388. Epub 2013 Jun 7. J Immunotoxicol. 2014. PMID: 23746314 Free article. Review.

2

HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach.

Lebrec H, Brennan FR, Haggerty H, Herzyk D, Kamperschroer C, Maier CC, Ponce R, Preston BD, Weinstock D, Mellon RD. Lebrec H, et al. Regul Toxicol Pharmacol. 2016 Mar;75:72-80. doi: 10.1016/j.yrtph.2015.12.018. Epub 2015 Dec 29. Regul Toxicol Pharmacol. 2016. PMID: 26743742 Free article.

3

Nonclinical safety assessment of engineered T cell therapies.

Lebrec H, Maier CC, Maki K, Ponce R, Shenton J, Green S. Lebrec H, et al. Regul Toxicol Pharmacol. 2021 Dec;127:105064. doi: 10.1016/j.yrtph.2021.105064. Epub 2021 Oct 14. Regul Toxicol Pharmacol. 2021. PMID: 34656748 Free article. Review.

4

Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk.

Lebrec H, Ponce R, Preston BD, Iles J, Born TL, Hooper M. Lebrec H, et al. Curr Med Res Opin. 2015 Mar;31(3):557-74. doi: 10.1185/03007995.2015.1011778. Epub 2015 Feb 16. Curr Med Res Opin. 2015. PMID: 25651481 Review.

5

Preclinical safety, pharmacokinetics, and pharmacodynamics of recombinant human interleukin-21 in cynomolgus macaques (Macaca fascicularis).

Waggie KS, Holdren MS, Byrnes-Blake K, Pedersen S, Ponce R, Hughes S, Miller DM. Waggie KS, et al. Int J Toxicol. 2012 Jul-Aug;31(4):303-16. doi: 10.1177/1091581812449661. Epub 2012 Jun 21. Int J Toxicol. 2012. PMID: 22723515

6

Safety assessment of immunomodulatory biologics: the promise and challenges of regulatory T-cell modulation.

Ponce RA. Ponce RA. J Immunotoxicol. 2011 Oct-Dec;8(4):389-97. doi: 10.3109/1547691X.2011.603390. Epub 2011 Sep 14. J Immunotoxicol. 2011. PMID: 21913866 Free article.

7

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. Ponce R, et al. Regul Toxicol Pharmacol. 2009 Jul;54(2):164-82. doi: 10.1016/j.yrtph.2009.03.012. Epub 2009 Apr 2. Regul Toxicol Pharmacol. 2009. PMID: 19345250

8

Influenza virus host response of C57Bl/6 mice treated with TACI-Ig.

Roque R, Ponce R, Burleson F, Cabrit M, Broly H, Rogge M. Roque R, et al. Immunopharmacol Immunotoxicol. 2006;28(1):13-32. doi: 10.1080/08923970600623541. Immunopharmacol Immunotoxicol. 2006. PMID: 16684665

9

Adverse consequences of immunostimulation.

Ponce R. Ponce R. J Immunotoxicol. 2008 Jan;5(1):33-41. doi: 10.1080/15476910801897920. J Immunotoxicol. 2008. PMID: 18382856 Free article.

10

Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.

Vahle JL, Finch GL, Heidel SM, Hovland DN Jr, Ivens I, Parker S, Ponce RA, Sachs C, Steigerwalt R, Short B, Todd MD. Vahle JL, et al. Among authors: ponce ra. Toxicol Pathol. 2010 Jun;38(4):522-53. doi: 10.1177/0192623310368984. Epub 2010 May 14. Toxicol Pathol. 2010. PMID: 20472697 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters